Researchers Report Proof-of-Principle Findings on Sequencing-Based Cancer Gene Profiling Approach | GenomeWeb

This article has been corrected to note that the mean coverage was 391 times, not 102 times as cited in the original article.

By Andrea Anderson

CHICAGO (GenomeWeb News) – A team of researchers led by investigators at the Dana-Farber Cancer Institute have developed a massively-parallel sequencing strategy for profiling "actionable" cancer genes from formalin-fixed paraffin-embedded tumor samples, Dana-Farber oncologist Nikhil Wagle reported at the American Society of Clinical Oncology annual meeting.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

Feb
25
Sponsored by
Omicia

This webinar will demonstrate how ACMG's recommended variant scoring and classification rules may be applied to standardize reporting on sequencing test results within and across institutions. 

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies. 

Mar
17
Sponsored by
Qiagen

This webinar will discuss Qiagen's approach to address two challenges facing NGS in the clinical research setting: lack of seamless workflow for routine clinical research use and truly relevant content to guide clinical research activities.